150 related articles for article (PubMed ID: 29737473)
1. Uptake of BRCA 1/2 and oncotype DX testing by medical and surgical oncologists.
Murciano-Goroff YR; McCarthy AM; Bristol MN; Groeneveld P; Domchek SM; Motanya UN; Armstrong K
Breast Cancer Res Treat; 2018 Aug; 171(1):173-180. PubMed ID: 29737473
[TBL] [Abstract][Full Text] [Related]
2. Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations.
Lewin R; Sulkes A; Shochat T; Tsoref D; Rizel S; Liebermann N; Hendler D; Neiman V; Ben-Aharon I; Friedman E; Paluch-Shimon S; Margel D; Kedar I; Yerushalmi R
Breast Cancer Res Treat; 2016 Jun; 157(3):511-6. PubMed ID: 27225387
[TBL] [Abstract][Full Text] [Related]
3. Impact of Genomic Assay Testing and Clinical Factors on Chemotherapy Use After Implementation of Standardized Testing Criteria.
Natsuhara KH; Losk K; King TA; Lin NU; Camuso K; Golshan M; Pochebit S; Brock JE; Bunnell CA; Freedman RA
Oncologist; 2019 May; 24(5):595-602. PubMed ID: 30076279
[TBL] [Abstract][Full Text] [Related]
4. Oncotype Dx recurrence score among BRCA1/2 germline mutation carriers with hormone receptors positive breast cancer.
Halpern N; Sonnenblick A; Uziely B; Divinsky L; Goldberg Y; Hamburger T; Peretz T; Kadouri L
Int J Cancer; 2017 May; 140(9):2145-2149. PubMed ID: 28120435
[TBL] [Abstract][Full Text] [Related]
5. Patient-Centered Communication for Discussing Oncotype DX Testing.
Roberts MC; Bryson A; Weinberger M; Dusetzina SB; Dinan MA; Reeder-Hayes KE; Wheeler SB
Cancer Invest; 2016 May; 34(5):205-12. PubMed ID: 27124287
[TBL] [Abstract][Full Text] [Related]
6. Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status.
Shah PD; Patil S; Dickler MN; Offit K; Hudis CA; Robson ME
Cancer; 2016 Apr; 122(8):1178-84. PubMed ID: 26859126
[TBL] [Abstract][Full Text] [Related]
7. Factors affecting the adoption and use of gene expression profiling by oncologists in clinical practice.
Patil D; Issa AM
Per Med; 2015 Jan; 12(1):33-42. PubMed ID: 29767541
[TBL] [Abstract][Full Text] [Related]
8. ONCOLOGISTS' BARRIERS AND FACILITATORS FOR ONCOTYPE DX USE: QUALITATIVE STUDY.
Roberts MC; Bryson A; Weinberger M; Dusetzina SB; Dinan MA; Reeder-Hayes K; Wheeler SB
Int J Technol Assess Health Care; 2016 Jan; 32(5):355-361. PubMed ID: 27958190
[TBL] [Abstract][Full Text] [Related]
9. Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer.
Kapoor NS; Curcio LD; Blakemore CA; Bremner AK; McFarland RE; West JG; Banks KC
Ann Surg Oncol; 2015 Oct; 22(10):3282-8. PubMed ID: 26219241
[TBL] [Abstract][Full Text] [Related]
10. BRCA1 and BRCA2 Mutation Testing in Young Women With Breast Cancer.
Rosenberg SM; Ruddy KJ; Tamimi RM; Gelber S; Schapira L; Come S; Borges VF; Larsen B; Garber JE; Partridge AH
JAMA Oncol; 2016 Jun; 2(6):730-6. PubMed ID: 26867710
[TBL] [Abstract][Full Text] [Related]
11. Does knowledge about the genetics of breast cancer differ between nongeneticist physicians who do or do not discuss or order BRCA testing?
Doksum T; Bernhardt BA; Holtzman NA
Genet Med; 2003; 5(2):99-105. PubMed ID: 12644779
[TBL] [Abstract][Full Text] [Related]
12. Physicians' experiences with BRCA1/2 testing in community settings.
Keating NL; Stoeckert KA; Regan MM; DiGianni L; Garber JE
J Clin Oncol; 2008 Dec; 26(35):5789-96. PubMed ID: 19001322
[TBL] [Abstract][Full Text] [Related]
13. Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers.
Grindedal EM; Heramb C; Karsrud I; Ariansen SL; Mæhle L; Undlien DE; Norum J; Schlichting E
BMC Cancer; 2017 Jun; 17(1):438. PubMed ID: 28637432
[TBL] [Abstract][Full Text] [Related]
14. Surgeon and medical oncologist peer network effects on the uptake of the 21-gene breast cancer recurrence score assay.
Zipkin R; Schaefer A; Chamberlin M; Onega T; O'Malley AJ; Moen EL
Cancer Med; 2021 Feb; 10(4):1253-1263. PubMed ID: 33455068
[TBL] [Abstract][Full Text] [Related]
15. BRCA to the future: towards best testing practice in the era of personalised healthcare.
Capoluongo E
Eur J Hum Genet; 2016 Sep; 24 Suppl 1(Suppl 1):S1-2. PubMed ID: 27514838
[No Abstract] [Full Text] [Related]
16. Clinical outcomes and Oncotype DX Breast Recurrence Score® in early-stage BRCA-associated hormone receptor-positive breast cancer.
Layman RM; Lin H; Gutierrez Barrera AM; Karuturi MS; Yam C; Arun BK
Cancer Med; 2022 Mar; 11(6):1474-1483. PubMed ID: 35128817
[TBL] [Abstract][Full Text] [Related]
17. Tissue-based predictors of germ-line BRCA1 mutations: implications for triaging of genetic testing.
de la Cruz J; Andre F; Harrell RK; Bassett RL; Arun B; Mathieu MC; Delaloge S; Gilcrease MZ
Hum Pathol; 2012 Nov; 43(11):1932-9. PubMed ID: 22591913
[TBL] [Abstract][Full Text] [Related]
18. Germline BRCA testing is moving from cancer risk assessment to a predictive biomarker for targeting cancer therapeutics.
Moreno L; Linossi C; Esteban I; Gadea N; Carrasco E; Bonache S; Gutiérrez-Enríquez S; Cruz C; Díez O; Balmaña J
Clin Transl Oncol; 2016 Oct; 18(10):981-7. PubMed ID: 26742938
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer, BRCA mutations, and attitudes regarding pregnancy and preimplantation genetic diagnosis.
Woodson AH; Muse KI; Lin H; Jackson M; Mattair DN; Schover L; Woodard T; McKenzie L; Theriault RL; Hortobágyi GN; Arun B; Peterson SK; Profato J; Litton JK
Oncologist; 2014 Aug; 19(8):797-804. PubMed ID: 24951607
[TBL] [Abstract][Full Text] [Related]
20. The value of personalizing medicine: medical oncologists' views on gene expression profiling in breast cancer treatment.
Bombard Y; Rozmovits L; Trudeau M; Leighl NB; Deal K; Marshall DA
Oncologist; 2015 Apr; 20(4):351-6. PubMed ID: 25746345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
